Therapeutic Classification: agents for atypical mycobacterium, anti-infectives
Pharmacologic Classification: macrolides
REMS
Mycobacterium avium
complex (MAC) infection in patients with advanced HIV infection.Spectrum:
Absorption: Rapidly absorbed (40%) after oral administration. IV administration results in complete bioavailability.
Distribution: Widely distributed to body tissues and fluids. Intracellular and tissue levels exceed those in serum; low CSF levels.
Protein Binding: 751%.
Half-Life: 1114 hr after single dose; 24 days after several doses.
Contraindicated in:
Use Cautiously in:
CV: CARDIOVASCULAR DEATH, chest pain, hypotension, palpitations, QT interval prolongation, TORSADES DE POINTES
Derm: ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), photosensitivity, rash, STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS
EENT: ototoxicity
F and E: hyperkalemia
GI: abdominal pain, diarrhea, nausea, ↑liver enzymes, cholestatic jaundice, CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD), dyspepsia, flatulence, HEPATOTOXICITY, melena, oral candidiasis, pyloric stenosis
GU: nephritis, vaginitis
Hemat: anemia, leukopenia, thrombocytopenia
Neuro: dizziness, drowsiness, fatigue, headache, seizures
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)
Drug-drug:
Most Respiratory and Skin Infections
Otitis Media
Acute Bacterial Exacerbations of Chronic Bronchitis
Community-Acquired Pneumonia
Endocarditis Prophylaxis
Nongonococcal Urethritis, Cervicitis, Chancroid, Chlamydia
Gonorrhea
Prevention of Disseminated MAC Infection
Cystic Fibrosis
Lab Test Considerations:
IV Administration:
NDC Code